Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Early Response to MASH Drug Linked to Resolution, Fibrosis Improvement

(MedPage Today) -- In patients treated with resmetirom (Rezdiffra), early responses in blood and imaging biomarkers were associated with resolution of metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis improvement, according to...

Early Response to MASH Drug Linked to Resolution, Fibrosis Improvement

We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.

Read the original at medpagetoday.com →

More in Health & Medicine

More from Monday 9 November →